Synta reports positive ganetespib results
January 2014

LEXINGTON, Mass.—Synta Pharmaceuticals Corp. has announced a pair of published preclinical studies recently supporting the activity of ganetespib, a potent, selective inhibitor of the Hsp90 chaperone protein, as well as recent results from a clinical treatment setting of triple-negative breast cancer—the drug is being studied in more than 25 clinical trials overall. The publications demonstrate that the compound is capable of down-regulating several key proteins related to tumor growth and metastasis, including HIF- 1alpha, which is a key regulator of multiple tumor growth properties such as angiogenesis, metastasis, metabolism, cancer stem cell maintenance and invasion. In addition, the publications showed that inhibiting several protein targets, including HIF-1alpha, correlates with potent effects on the viability and metastasis of triple-negative breast cancer tumor cells when ganetespib is administered alone or in combination with other chemotherapeutics.

1000 N West Street, Suite 1200,
Wilmington, Delaware, 19801
Ph: 888-781-0328 |  Fax: 705-528-0270
© Copyright 2020 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.